Kornimate/medical-research-clean huggingface dataset:
evaluation of the prevalence of anomalies of glucose metabolism in patients undergoing a coronary artery bypass graft (cabg)

Conditions: Anomalies in Glucose Metabolism; Coronary Artery Bypass Graft

Summary: the aim of this study is to determine the prevalence of diabetes and non-diabetic glucose metabolism anomalies (glucose intolerance, non-diabetic fasting hyperglycaemia in patients about to undergo coronary artery bypass grafting (cabg). in addition, the effect of these anomalies on post cabg morbi/mortality in the short term will be evaluated.


Eligibility criteria:
inclusion criteria: * persons who have provided oral consent * patients about to undergo coronary artery bypass grafting * age \>18 years exclusion criteria: * persons without national health insurance cover * adults under guardianship * pregnant or breast-feeding women
incentives for oklahoma tobacco helpline engagement in persistent poverty counties

Conditions: Cigarette Smoking; Nicotine Dependence

Summary: the proposed pilot project is designed to evaluate the feasibility and potential efficacy of offering small financial incentives for the completion of smoking cessation counseling and self-reported abstinence at follow-up among oklahoma tobacco helpline (oth) callers living in persistent poverty counties (ppcs). the study will enroll at least 160 adults who reside in any of the 16 persistent poverty counties in oklahoma, who are seeking smoking cessation treatment through the oth.

the proposed randomized controlled trial will enroll adults who are seeking smoking cessation treatment through the oth and who reside in any of the 16 ppcs in oklahoma. participants will be randomly assigned to oth (coaching calls + nicotine replacement therapy) or oth plus escalating financial incentives (oth+fi) for completing up to 5 counseling calls over 8 weeks. feasibility outcomes for the incentives-based intervention will focus on counseling call completions, follow-up assessment completion, smoking cessation, and incentive costs. potential effectiveness will be evaluated based on comparisons of counseling call completions over the first 8 weeks post-enrollment and rates of self-reported smoking abstinence through 12 weeks post-enrollment (4 weeks after incentives have ended) in oth+fi relative to oth alone.

Eligibility criteria:
inclusion criteria: 1. contact the oth seeking smoking cessation treatment 2. reside in any of the 16 ppcs in oklahoma (adair, caddo, cherokee, choctaw, greer, harmon, haskell, hughes, johnston, mccurtain, okfuskee, payne, pushmataha, seminole, sequoyah, tillman) 3. report smoking ≥ 5 cigarettes per day 4. are ≥ 18 years of age 5. are able to provide a copy/photo of their id/driver's license or other documentation of identity and residence 6. be able to read, speak, and understand english 7. have no contradictions for nrt

Keywords: persistent poverty smoking cessation financial incentives contingency management tobacco helpline tobacco quitline socioeconomic status
prevalence of sexually transmitted infections (stis) and coinfections in the general population

Conditions: HIV Infections

Summary: prevalence of sexually transmitted infections (stis) and co-infections in the general population


Eligibility criteria:
inclusion criteria: * subject, male or female, 18 years of age or older * subject capable of understanding the purpose of the research having given their free and informed written consent * subject presenting to the laboratory for a biological examination * affiliated subject or beneficiary of a social security scheme exclusion criteria: - protected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
personalized blood flow restriction for anterior cruciate ligament rehabilitation

Conditions: Anterior Cruciate Ligament Tear

Summary: this is a cross-sectional study on the use of personalized blood flow restriction during rehabilitation exercises and its effects on biomechanics on people who have had an anterior cruciate ligament reconstruction and healthy controls

rehabilitation after surgical reconstruction of the anterior cruciate ligament (acl) aims to reestablish the function of the knee. however, regaining previous levels of strength is challenging, with long-term muscle weakness frequently reported and thought to play a key role in the increased risk of knee osteoarthritis for individuals with a history of acl damage. effectively building muscle strength requires exercises with high resistance loads, however the joint stress and risk of further injury makes these types of activities inappropriate and unsafe for those rehabilitating after acl reconstruction surgery and other injuries. personalized blood flow restriction (bfr) training is a technique where the blood flow to the muscles being exercised is controlled by a pressure cuff to a predefined level, and has been shown to increase strength while exercising with significantly lower loads. early results have been promising, however the effects of bfr on the biomechanics of the exercise as well as the acceptability in the acl reconstruction population have not been explored. in this application, we propose a cross-sectional study designed to test the acceptability of bfr training for those undergoing rehabilitation from acl reconstruction surgery and healthy controls during free standing exercises. we will also investigate the biomechanical effects of this rehabilitation technique. this application is part of a larger program of musculoskeletal research in this area being developed by the team. the results from the proposed project will inform the design of a clinical trial of personalized bfr after acl reconstruction.

Eligibility criteria:
inclusion criteria (acl-r group): * must be undergoing rehabilitation for anterior cruciate ligament reconstruction surgery * must be at least 3 months post surgery. * attending clinician should confirm that they are able to take part in the trial exclusion criteria: * any other orthopaedic, neurological, or other condition within the last 12 months that would affect ability to carry out the required exercises * any medical conditions that may affect circulation including, but not limited to, deep vein thrombosis, high blood pressure, and cardiac disease
stress reduction intervention for women with ischemic heart disease

Conditions: Ischemic Heart Disease

Summary: this is a single center, randomized controlled trial which will include women with ischemic heart disease to receive either a self-directed stress reduction program delivered through a smart-phone application or activity tracking only for the first month ("early sr intervention" and "delayed sr intervention", respectively). patients will be monitored for 1 month for application use and step counts via telephone or email interview and/or collection of screen-captured data. baseline questionnaires will be repeated at the end of one month to assess for all primary and secondary measures, at which time the control group (activity tracking only) will be introduced to the intervention program. the early sr intervention group will not receive a new intervention but will be encouraged to continue using the app. data will be collected for an additional 2 months with all participants in both groups. after the three-month study period, the study will close with the collection of final questionnaire data.


Eligibility criteria:
inclusion criteria: * presence of ischemic heart disease as defined by one or more of the following within the last 2 years: * positive stress test * admission for acs, pci, or cabg * typical or atypical ischemic symptoms within one month of enrollment * on stable dose of anti-anginal medications for at least 2 months * able and willing to provide informed consent and comply with all aspects of the protocol * owns a smartphone with the ability to download applications for stress reduction and activity tracking * english-speaking (apps are not available in other languages) exclusion criteria: * planned for revascularization during the study period * self-reported or chart-reviewed diagnosis of psychotic disorder including schizophrenia or schizoaffective disorder, bipolar disorder * current participation in a cardiac rehab program or planned participation during the study period
multimodal analgesic management of naborphine combined with opioid free anesthesia in osa patients undergoing bariatric surgery

Conditions: Analgesics，Opioid; Bariatric Surgery

Summary: comparative study to explore the effect of opioid free anesthesia technology in perioperative analgesia management, clarify the effect of naborphine instead of opioids on perioperative analgesia management in morbid obesity patients with moderate and severe osa, reduce related adverse events, and explore the latest clinical anesthetic drugs.

1. the concept of enhanced recovery after surgery (eras) has been applied in the perioperative period of many operations. reducing the dosage of opioids is an important part of the concept of eras. 2. opioid free anesthesia technology has been recognized in reducing nausea and vomiting, but whether it can meet the perioperative analgesic needs of patients undergoing bariatric surgery and obtain more clinical benefits still has no research supportment. 3. this study is expected to clarify the clinical effect of opioid free anesthesia technology in perioperative analgesia management of morbid obesity patients with moderate and severe osa, reduce adverse events, and explore the latest clinical anesthesia scheme.

Eligibility criteria:
inclusion criteria: 1. asa grade i \~ iii; 2. age from 18 - 65 years old; 3. bmi ≥ 35kg / m2 in patients with osa to undergo bariatric surgery； （4 provide written informed consent for participation. exclusion criteria: 1. age \ 65 years old; 2. pregnancy test was positive; 3. patients with a history of drug abuse or dependence on opioids; 4. patients with chronic pain or severe heart, lung, liver or nervous system diseases

Keywords: opioid free anesthesia bariatric surgery eras
dorado-ac - optimized doses of darusentan as compared to an active control in resistant hypertension

Conditions: Hypertension

Summary: this is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. darusentan is not currently approved by the united states food and drug administration (fda), which means that a doctor cannot prescribe this drug. the purpose of this study is to determine if darusentan is effective in reducing systolic and diastolic hypertension despite treatment with full doses of three or more antihypertensive drugs, including a diuretic. subjects will be randomized to darusentan (optimized dose), an active comparator, or placebo, administered orally. the treatment period for this trial is 14 weeks.


Eligibility criteria:
selected inclusion criteria: 1. subjects who are competent to provide written consent; 2. aged 35 to 80 years; 3. subjects with diabetes and/or chronic kidney disease must have an average sitting systolic blood pressure greater than or equal to 130 mmhg; 4. all other subjects must have an average sitting systolic blood pressure greater than or equal to 140 mmhg; 5. receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic; 6. female subjects of non-childbearing potential (i.e., post-menopausal for at least 2 years or surgically sterile). selected exclusion criteria: 1. average sitting systolic and diastolic blood pressure greater than or equal to 180 mmhg and 110 mmhg, respectively; 2. subjects treated with a central alpha-2 agonist and/or imidazoline receptor agonist; 3. left ventricular dysfunction; 4. serum alt or ast greater than 2 times the upper limit of normal; 5. subjects who have experienced myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months; or sick sinus syndrome or second or third degree atrioventricular block, atrial fibrillation or recurrent atrial tachycardia, recurrent ventricular tachycardia, or symptomatic bradycardia; 6. implanted pacemakers or cardioverter defibrillator; 7. symptomatic congestive heart failure requiring treatment; 8. hemodynamically significant valvular heart disease; 9. hemodialysis or peritoneal dialysis, or history of renal transplant; 10. type i diabetes mellitus; 11. diagnosis or recurrence of malignancy within the past 3 years; 12. sleep apnea, unless a recent sleep study demonstrated arterial oxygenation saturation greater than or equal to 90%, treated or untreated; 13. subjects who perform alternating shift or night work; 14. subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to screening
graston vs manual myofascial release technique in piriformis syndrome.

Conditions: Piriformis Syndrome

Summary: the objective of our study is to compare the effects of graston and manual myofascial release technique on pain, muscle length and functional status in patients with piriformis syndrome.

in 2019, a study was conducted to conclude the effectiveness of passive stretching v/s myofascial release in improving piriformis flexibility in females. they reported that myofascial release was more valuable than passive stretching exercises in enhancing piriformis flexibility in patients with piriformis tightness. according to another study in 2018, after a single treatment, compressive myofascial release showed more improvement in ankle dorsiflexion than graston technique, in participants with decrease dorsiflexion range. in 2016, a study reported the effects of the graston technique and general exercise in patients with chronic low back pain. graston group showed greater improvement in pain and range of motion in patients with chronic low back pain. according to a study conducted in 2014, self-myofascial release was more effective than graston technique in improving knee joint flexibility, hamstring, and quadriceps strength. in 2011, a study evaluated the effectiveness of deep soft tissue mobilization techniques and stretching exercises in piriformis syndrome and found that the deep soft tissue mobilization techniques along with stretching exercises significantly improved the piriformis syndrome.

Eligibility criteria:
inclusion criteria:• * pain more than 1 month. * piriformis syndrome diagnosed through screening test (fair test, beatty test, freiberg test, sign of pace) exclusion criteria: * leg pain due to causes other than piriformis syndrome. * congenital spinal deformity. * history of fracture. * history of back or hip surgery. * any systemic illness like metastatic or infective disorders.

Keywords: graston technique myofascial release lower extremity functional scale piriformis syndrome
tenofovir df (disoproxil fumarate) in combination with emtricitabine in hiv-1 patients

Conditions: HIV Infections

Summary: the purpose of this study is to provide long-term clinical safety and efficacy data for tenofovir disoproxil fumarate and emtricitabine in hiv-infected patients experiencing various degrees of renal impairment.

the primary objective of this study is as follows: * to evaluate the safety and tolerability of tenofovir following administration of tenofovir disoproxil fumarate 300 mg for 48 weeks in hiv-infected patients experiencing various degrees of renal impairment. the secondary objectives of this study are as follows: * to evaluate the safety and tolerability of emtricitabine following administration of emtricitabine 200 mg for 48 weeks in hiv-infected patients experiencing various degrees of renal impairment. * to evaluate the efficacy of tenofovir disoproxil fumarate in combination with emtricitabine in renally-impaired hiv-infected patients. * to evaluate the pharmacokinetics of tenofovir and emtricitabine in renally-impaired hiv-infected patients.

Eligibility criteria:
inclusion criteria: patients must meet all of the following inclusion criteria to be eligible for participation in the study. * hiv-1 infection * either antiretroviral therapy-naive requiring antiretroviral treatment with hiv-1 rna greater than 400 copies/ml or antiretroviral therapy-experienced on a stable antiretroviral regimen for at least 3 mos. with hiv-1 rna less than or equal to 50 copies/ml at screening. * no active opportunistic infection within 45 days prior to baseline. * able to understand and sign the informed consent form and comply with the study. * stable renal impairment within the four defined groups for at least 3 mos., based on creatinine clearance (cockcroft-gault method). exclusion criteria: patients who meet any of the following are not to be enrolled in this study. * women who are pregnant or breastfeeding * fanconi syndrome or multiple myeloma, tertiary hyperparathyroidism, malignancy (with the exception of basocellular carcinoma) or myeloproliferative disorder. * women of childbearing potential who are unwilling to use an effective contraceptive method during the study * contraindications to tenofovir df, emtricitabine or efavirenz * undergoing treatment for tuberculosis * using atazanavir * prior history of mutation m184v, k65r or t69 insertion * z-score on pre-baseline dexa scan less than -2.5 * the following laboratory values within 30 days prior to study entry: \*absolute neutrophil count (anc) less than 750/mm3, \*hemoglobin less than 9.0 g/dl, \*platelet count less than 50,000/mm3, \*ast (sgot) or alt (sgpt) less than 5 x uln and \*cd4 cell count less than 100/mm3. * use of nephrotoxic agents or competitors with renal excretions, including aminoglycoside antibiotics, intravenous amphotericin b, cidofovir, cisplatin, foscarnet, intravenous pentamidine, probenecid or other agents with significant nephrotoxic potential * clinically significant cardiac, pulmonary or gastrointestinal disorder * alcohol or drug abuse that could hinder compliance with the study

Keywords: hiv-1 treatment naive treatment experienced
wearable device-based analysis of the relationship between sleep patterns and clinical prognosis in patients with traumatic brain injury

Conditions: Traumatic Brain Injury (TBI); Concussion, Initial Encounter

Summary: in patients with traumatic brain injury, post-traumatic sleep patterns have the potential to impact clinical prognosis. while some progress has been made in the study of sleep and prognosis in patients with traumatic brain injury, there is still lack of research on the relationship between sleep and clinical prognosis in post-traumatic patients due to differences in study design, patient age, severity of trauma, and definitions of sleep disorders. additionally, the primary data collection methods employed in most studies have been self-reported sleep assessments, which are subject to potential biases and inaccuracies. therefore, explore the impact of sleep patterns on clinical prognosis in post-traumatic patients, with potential to advance our comprehension of recovery outcomes in this patient group.


Eligibility criteria:
inclusion criteria: 1. 18\~60 years old. 2. the patient had no sleep disturbance problems prior to traumatic brain injury. 3. the patient has a definite diagnosis of traumatic brain injury and the glasgow score is \>8. 4. the patient had abnormal imaging scans. 5. it has complete preclinical data. exclusion criteria: 1. patients with a previous history of traumatic brain injury, mental illness, alcohol abuse or sleep disorders. 2. patients admitted for surgical intervention. 3. patients with a combination of other heavy visceral injuries. 4. women during pregnancy and lactation. 5. the patents' use of medications that interfere with sleep

Keywords: traumatic brain injury sleep prognosis of trauma wearable devices
integrating safer conception counseling to transform hiv family planning services

Conditions: Safer Conception Intervention Trial

Summary: this 3-arm cluster randomized controlled trial (rct) will compare (1) a comprehensive family planning (fp) program that incorporates a structured, multi-component safer conception counseling (scc) intervention (scc1) versus (2) a scc training workshop for fp nurses (scc2; less intensive and mimics approach used by ugandan ministry of health (moh) to integrate new services), and (3) existing fp services (usual care) at 9 hiv clinics (3 per arm) operated by the aids support organization (taso) uganda.

family planning (fp) services for people living hiv/aids (plha) focus on preventing unplanned pregnancies and mother-to-child-transmission (pmtct), and currently provide no services to support safer conception, despite \~40% of hiv+ women in sub-saharan africa (ssa) becoming pregnant post hiv diagnosis. antiretroviral therapy (art) greatly reduces the transmission risks associated with childbearing, but many plha are either not on art or not adequately adherent; hence the need for using safer conception methods (scm) such as manual self-insemination and timed unprotected intercourse. this cluster rct will compare (1) a comprehensive fp program that incorporates a structured, multi-component scc intervention (scc1) versus (2) an scc training workshop for fp nurses (scc2; mimics approach used by ugandan moh to integrate new services), and (3) existing fp services (usual care) at 6 hiv clinics operated by taso uganda. the 3-arm design, together with the planned cost-effectiveness analysis, allows us to examine two models for integrating scc into fp services that differ on level of intensity, thereby informing moh policy and resource allocation. sixty clients in hiv serodiscordant relationships who express childbearing desires at recruitment will be enrolled at each site (n=360) and followed for 12 months or completion of pregnancy (if applicable). the primary outcome is use of either scm (for those trying to conceive) or dual contraception (those who decide against pregnancy).

Eligibility criteria:
inclusion criteria: 1. hiv+ client of taso 2. client if of reproductive age (males age 15-60; females age 15-45). 3. has a partner with whom the client is considering having a child. 4. if client or their partner is age 15-17, the couple must be "married", defined as cohabitating and the parents of the minor(s) are reported to be aware of the relationship. 5. partner with whom the client is considering having a child is hiv-negative. 5. client reports that their partner is aware of the client being hiv-positive. exclusion criteria: 1. female client (or partner of male client) is pregnant

Keywords: family planning safer conception hiv serodiscordant couples uganda contraception